IceCure Medical Ltd (NASDAQ:ICCM) Q1 2023 Earnings Conference Call May 22, 2023 10:00 AM ET
Company Participants
Todd Kehrli - EVC Group, IR
Eyal Shamir - Chief Executive Officer
Tlalit Bussi Tel-Tzure - Vice President, Business Development and Global Marketing
Ronen Tsimerman - Chief Financial Officer and COO
Conference Call Participants
Chait G - H.C. Wainwright
Anthony Vendetti - Maxim Group
Kemp Dolliver - Brookline Capital Markets
Operator
Good morning and thank you for standing by. Currently, all participants are in a listen-only mode. After management’s discussion there will be a question-and-answer session. Please be advised that today’s conference call is being recorded.
I would now like to turn the conference over to Todd Kehrli. Please go ahead.
Todd Kehrli
…ended March 31, 2023, and provide an update on recent operational highlights. You may refer to the earnings press release that we issued early this morning.
Participating on this morning’s call are IceCure Medical’s CEO, Eyal Shamir; and VP of Business Development and Global Marketing, Tlalit Bussi Tel-Tzure; and the company’s CFO and COO, Ronen Tsimerman. After the prepared comments, management will make -- will be available to address your questions.
Before we begin, I will take a moment now to read a statement about forward-looking statements. This call and the question-and-answer session that follow contain forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws.
Words such as expects, anticipates, intends, plans, believes, seeks, could, estimates and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements in this presentation when we discuss during this conference call that we will hold courses or master classes as part of future conferences or our plans to exhibit our technology at future conferences and believe that there will be a rapid adoption of ProSense with the indication of early-stage with high risk to surgery breast cancer if it receives FDA approval.
Because such statements deal with future events and are based on IceCure’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of IceCure could differ materially from those described in or implied by our statements in this presentation.
The forward-looking statements contained or implied in this presentation are subject to other risks and uncertainties, many of which are beyond the control of the company, including those set forth in the Risk Factors section of the company’s annual report on Form 20-F for the year ended December 31, 2022, filed with the SEC on March 29, 2023, which is available on the SEC’s website at www.sec.gov. The company undertakes no obligation to update these statements for revisions or changes after the call -- after the date of this call, except as required by law.